A South African AIDS patient holds his antiretroviral medication. (Gideon Mendel / Corbis) Gideon Mendel / Corbis

Ends and means

Researchers developing AIDS drugs must balance their pursuit of effective treatments with the well-being of the people they're testing. Two controversial new books suggest that too often the good of the trial comes before the good of the subject.

By Jessica Winter

July 2, 2006

E-mail|
Reprints|

Text size – +

LAST MARCH, Harper's Magazine published an article by journalist Celia Farber called ``Out of Control: AIDS and the Corruption of Medical Science." The piece focused on the death of 33-year-old Joyce Ann Hafford, a pregnant, HIV-positive woman in Tennessee who died of liver failure after enrolling in a clinical trial of the drug nevirapine, manufactured by the German pharmaceutical company ... (Full article: 1946 words)